Business Description
MaxCyte Inc
NAICS : 334510
SIC : 3845
ISIN : US57777K1060
Description
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 8.49 | |||||
Equity-to-Asset | 0.88 | |||||
Debt-to-Equity | 0.08 | |||||
Debt-to-EBITDA | -0.44 | |||||
Interest Coverage | N/A | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 7.24 | |||||
Beneish M-Score | 27.84 | |||||
WACC vs ROIC |
Growth Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 4.1 | |||||
3-Year EBITDA Growth Rate | -47.2 | |||||
3-Year EPS without NRI Growth Rate | -32.3 | |||||
3-Year FCF Growth Rate | -18.7 | |||||
3-Year Book Growth Rate | 60 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 15.3 |
Momentum Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 24.58 | |||||
9-Day RSI | 28.38 | |||||
14-Day RSI | 33.58 | |||||
6-1 Month Momentum % | 7.02 | |||||
12-1 Month Momentum % | 3.39 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 14.31 | |||||
Quick Ratio | 13.4 | |||||
Cash Ratio | 12.82 | |||||
Days Inventory | 820.09 | |||||
Days Sales Outstanding | 51.77 | |||||
Days Payable | 75.23 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -21.9 | |||||
Shareholder Yield % | -0.35 |
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 88.44 | |||||
Operating Margin % | -102.14 | |||||
Net Margin % | -78.21 | |||||
FCF Margin % | -56.1 | |||||
ROE % | -15.37 | |||||
ROA % | -13.49 | |||||
ROIC % | -61.12 | |||||
3-Year ROIIC % | -49.44 | |||||
ROC (Joel Greenblatt) % | -113.07 | |||||
ROCE % | -18.65 |
GF Value Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 8.53 | |||||
PB Ratio | 1.78 | |||||
Price-to-Tangible-Book | 1.79 | |||||
EV-to-EBIT | -5.64 | |||||
EV-to-EBITDA | -6.23 | |||||
EV-to-Forward-EBITDA | -10.6 | |||||
EV-to-Revenue | 5.76 | |||||
EV-to-Forward-Revenue | 5.6 | |||||
EV-to-FCF | -10.11 | |||||
Price-to-Projected-FCF | 10.24 | |||||
Price-to-Net-Current-Asset-Value | 2.73 | |||||
Price-to-Net-Cash | 3.13 | |||||
Earnings Yield (Greenblatt) % | -17.73 | |||||
FCF Yield % | -6.43 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
MaxCyte Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 41.99 | ||
EPS (TTM) (€) | -0.316 | ||
Beta | 1.89 | ||
Volatility % | 75.09 | ||
14-Day RSI | 33.58 | ||
14-Day ATR (€) | 0.129267 | ||
20-Day SMA (€) | 3.553 | ||
12-1 Month Momentum % | 3.39 | ||
52-Week Range (€) | 2.32 - 4.96 | ||
Shares Outstanding (Mil) | 105.09 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
MaxCyte Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
MaxCyte Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
MaxCyte Inc Frequently Asked Questions
What is MaxCyte Inc(FRA:MYE0)'s stock price today?
When is next earnings date of MaxCyte Inc(FRA:MYE0)?
Does MaxCyte Inc(FRA:MYE0) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |